These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36878429)
1. Once-Daily Foscarnet Is Effective for Human Herpesvirus 6 Reactivation after Hematopoietic Stem Cell Transplantation. Vittayawacharin P; E'Leimat G; Lee BJ; Griffin S; Doh J; Nam H; Blodget E; Jeyakumar D; Kongtim P; Ciurea SO Transplant Cell Ther; 2023 Jun; 29(6):397.e1-397.e6. PubMed ID: 36878429 [TBL] [Abstract][Full Text] [Related]
2. Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. El Jurdi N; Rogosheske J; DeFor T; Bejanyan N; Arora M; Bachanova V; Betts B; He F; Holtan S; Janakiram M; Larson S; Maakaron J; Rashidi A; Warlick E; Wagner JE; Young JH; Weisdorf D; Brunstein CG Transplant Cell Ther; 2021 Jan; 27(1):84.e1-84.e5. PubMed ID: 33053448 [TBL] [Abstract][Full Text] [Related]
3. Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis. Ogata M; Satou T; Inoue Y; Takano K; Ikebe T; Ando T; Ikewaki J; Kohno K; Nishida A; Saburi M; Miyazaki Y; Ohtsuka E; Saburi Y; Fukuda T; Kadota J Bone Marrow Transplant; 2013 Feb; 48(2):257-64. PubMed ID: 22750998 [TBL] [Abstract][Full Text] [Related]
4. Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. Han TT; Zhang YN; Sun YQ; Kong J; Wang FR; Wang ZD; Cheng YF; Yan CH; Wang Y; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS Transpl Infect Dis; 2021 Jun; 23(3):e13544. PubMed ID: 33326670 [TBL] [Abstract][Full Text] [Related]
6. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Ishiyama K; Katagiri T; Hoshino T; Yoshida T; Yamaguchi M; Nakao S Bone Marrow Transplant; 2011 Jun; 46(6):863-9. PubMed ID: 20838386 [TBL] [Abstract][Full Text] [Related]
7. Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group. Ogata M; Takano K; Moriuchi Y; Kondo T; Ueki T; Nakano N; Mori T; Uoshima N; Nagafuji K; Yamasaki S; Shibasaki Y; Sakai R; Kato K; Choi I; Jo Y; Eto T; Kako S; Oshima K; Fukuda T Biol Blood Marrow Transplant; 2018 Jun; 24(6):1264-1273. PubMed ID: 29454651 [TBL] [Abstract][Full Text] [Related]
8. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Wang LR; Dong LJ; Zhang MJ; Lu DP Biol Blood Marrow Transplant; 2006 Oct; 12(10):1031-7. PubMed ID: 17067909 [TBL] [Abstract][Full Text] [Related]
9. High Incidence of Early Human Herpesvirus-6 Infection in Children Undergoing Haploidentical Manipulated Stem Cell Transplantation for Hematologic Malignancies. Perruccio K; Sisinni L; Perez-Martinez A; Valentin J; Capolsini I; Massei MS; Caniglia M; Cesaro S Biol Blood Marrow Transplant; 2018 Dec; 24(12):2549-2557. PubMed ID: 30067953 [TBL] [Abstract][Full Text] [Related]
10. Human herpesvirus 6-related pure red cell aplasia, secondary graft failure, and clinical severe immune suppression after allogeneic hematopoietic cell transplantation successfully treated with foscarnet. Lagadinou ED; Marangos M; Liga M; Panos G; Tzouvara E; Dimitroulia E; Tiniakou M; Tsakris A; Zoumbos N; Spyridonidis A Transpl Infect Dis; 2010 Oct; 12(5):437-40. PubMed ID: 20561301 [TBL] [Abstract][Full Text] [Related]
11. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation]. Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219 [TBL] [Abstract][Full Text] [Related]
12. Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Inui Y; Yakushijin K; Okamura A; Tanaka Y; Shinzato I; Nomura T; Ichikawa H; Mizutani Y; Kitao A; Kurata K; Kakiuchi S; Miyata Y; Sanada Y; Kitagawa K; Uryu K; Kawamoto S; Yamamoto K; Matsuoka H; Murayama T; Ito M; Minami H Transpl Infect Dis; 2019 Feb; 21(1):e13024. PubMed ID: 30414316 [TBL] [Abstract][Full Text] [Related]
13. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Ogata M; Satou T; Kadota J; Saito N; Yoshida T; Okumura H; Ueki T; Nagafuji K; Kako S; Uoshima N; Tsudo M; Itamura H; Fukuda T Clin Infect Dis; 2013 Sep; 57(5):671-81. PubMed ID: 23723198 [TBL] [Abstract][Full Text] [Related]
14. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease. Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656 [TBL] [Abstract][Full Text] [Related]
15. High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality. Winestone LE; Punn R; Tamaresis JS; Buckingham J; Pinsky BA; Waggoner JJ; Kharbanda S Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29181879 [TBL] [Abstract][Full Text] [Related]
16. Long-term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation. Iesato K; Hori T; Yoto Y; Yamamoto M; Inazawa N; Kamo K; Ikeda H; Iyama S; Hatakeyama N; Iguchi A; Sugita J; Kobayashi R; Suzuki N; Tsutsumi H Pediatr Int; 2018 Jun; 60(6):547-552. PubMed ID: 29542206 [TBL] [Abstract][Full Text] [Related]
17. Human CD134 (OX40) expressed on T cells plays a key role for human herpesvirus 6B replication after allogeneic hematopoietic stem cell transplantation. Nagamata S; Nagasaka M; Kawabata A; Kishimoto K; Hasegawa D; Kosaka Y; Mori T; Morioka I; Nishimura N; Iijima K; Yamada H; Kawamoto S; Yakushijin K; Matsuoka H; Mori Y J Clin Virol; 2018 May; 102():50-55. PubMed ID: 29494951 [TBL] [Abstract][Full Text] [Related]
18. Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft-vs-host disease prophylaxis compared with cord blood transplantation. Tamaki H; Ikegame K; Yoshihara S; Kaida K; Yoshihara K; Inoue T; Kato R; Nakata J; Fujioka T; Soma T; Okada M; Ogawa H Transpl Infect Dis; 2019 Jun; 21(3):e13073. PubMed ID: 30875143 [TBL] [Abstract][Full Text] [Related]
19. Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. Aoki J; Numata A; Yamamoto E; Fujii E; Tanaka M; Kanamori H Biol Blood Marrow Transplant; 2015 Nov; 21(11):2017-22. PubMed ID: 26226409 [TBL] [Abstract][Full Text] [Related]
20. Human Herpesvirus 6 Reactivation Evaluated by Digital Polymerase Chain Reaction and Its Association With Dynamics of CD134-Positive T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. Nakayama H; Yamazaki R; Kato J; Koda Y; Sakurai M; Abe R; Watanuki S; Sumiya C; Shiroshita K; Fujita S; Yamaguchi K; Okamoto S; Mori T J Infect Dis; 2019 Aug; 220(6):1001-1007. PubMed ID: 31063196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]